Catherine DiGiorgio, M.D., Boston, speaks with Dermatology Times about current and upcoming noninvasive body contouring devices and procedures.
Having trouble viewing? Click to download
The high-affinity interleukin 13 inhibitor lebrikizumab significantly improved atopic dermatitis manifestations and symptoms with a safety profile similar to placebo, according to results from a phase 2b randomized clinical trial.
A recent meta-analysis confirms cyclosporine as the most effective atopic dermatitis (AD) treatment at the molecular level, although dupilumab achieves broad cutaneous changes beyond those expected with specific Th2 inhibition.
The coronavirus has created a challenging environment for all dermatology practices. Todd Petersen, CEO of VitalSkin Dermatology, discusses how to make the most of a bad situation by using telemedicine, making plans to reopen and performing a strategic review of your practice.
Taking the time to analyze and benchmark your practice can help you both position it for sale and find the right buyer.
LEO Pharma announces azelaic acid foam 15% (Finacea) is now available on the market to treat inflammatory papules and pustules of mild-to-moderate rosacea.
LEO Pharma has entered into a license agreement with Oneness Biotech and Microbio Shanghai for the development and commercialization of the investigational drug FB825 for the treatment of atopic dermatitis and asthma.
Brodalumab, guselkumab, ixekizumab and risankizumab stood out among 15 biologic and oral medications as having the highest short- and long-term response rates for the treatment of moderate-to-severe plaque psoriasis, according to a recent meta-analysis.